Hospital Universitario Reina Sofia -ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2021

  1. SEOM Clinical Guideline of management of soft-tissue sarcoma (2020)

    Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 922-930

2019

  1. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer

    Anti-Cancer Drugs, Vol. 30, Núm. 6, pp. 628-635

2016

  1. Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study)

    Annals of Oncology, Vol. 27, pp. vi312

2011

  1. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: A Spanish group for research on sarcomas study

    Journal of Clinical Oncology, Vol. 29, Núm. 18, pp. 2528-2533

2010

  1. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: A Spanish Group for Sarcoma Research (GEIS) Study

    Annals of Oncology, Vol. 21, Núm. 7, pp. 1552-1557

2005

  1. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: A GEICO (Grupo Español de Investigación en Cáncer de Ovario) study

    Annals of Oncology, Vol. 16, Núm. 5, pp. 749-755

2003

  1. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: A study by the GEICAM group

    Annals of Oncology, Vol. 14, Núm. 6, pp. 833-842